Cargando…

Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine

Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been developed to complete the cancer research arsenal and overcome the limits of current preclinical models. They aim to represent the molecular and structural heterogeneity of the tumor micro-environment, and its co...

Descripción completa

Detalles Bibliográficos
Autores principales: Lê, Hélène, Seitlinger, Joseph, Lindner, Véronique, Olland, Anne, Falcoz, Pierre-Emmanuel, Benkirane-Jessel, Nadia, Quéméneur, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312903/
https://www.ncbi.nlm.nih.gov/pubmed/35884982
http://dx.doi.org/10.3390/biomedicines10071677
_version_ 1784753947386314752
author Lê, Hélène
Seitlinger, Joseph
Lindner, Véronique
Olland, Anne
Falcoz, Pierre-Emmanuel
Benkirane-Jessel, Nadia
Quéméneur, Eric
author_facet Lê, Hélène
Seitlinger, Joseph
Lindner, Véronique
Olland, Anne
Falcoz, Pierre-Emmanuel
Benkirane-Jessel, Nadia
Quéméneur, Eric
author_sort Lê, Hélène
collection PubMed
description Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been developed to complete the cancer research arsenal and overcome the limits of current preclinical models. They aim to represent the molecular and structural heterogeneity of the tumor micro-environment, and its complex network of interactions, with greater accuracy. They are more predictive of clinical outcomes, of adverse events, and of resistance mechanisms. Thus, they increase the success rate of drug development, and help clinicians in their decision-making process. Lung cancer remains amongst the deadliest of diseases, and still requires intensive research. In this review, we analyze the merits and drawbacks of the current preclinical models used in lung cancer research, and the position of tumoroids. The introduction of immune cells and healthy regulatory cells in autologous tumoroid models has enabled their application to most recent therapeutic concepts. The possibility of deriving tumoroids from primary tumors within reasonable time has opened a direct approach to patient-specific features, supporting their future role in precision medicine.
format Online
Article
Text
id pubmed-9312903
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-93129032022-07-26 Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine Lê, Hélène Seitlinger, Joseph Lindner, Véronique Olland, Anne Falcoz, Pierre-Emmanuel Benkirane-Jessel, Nadia Quéméneur, Eric Biomedicines Review Synthetic 3D multicellular systems derived from patient tumors, or tumoroids, have been developed to complete the cancer research arsenal and overcome the limits of current preclinical models. They aim to represent the molecular and structural heterogeneity of the tumor micro-environment, and its complex network of interactions, with greater accuracy. They are more predictive of clinical outcomes, of adverse events, and of resistance mechanisms. Thus, they increase the success rate of drug development, and help clinicians in their decision-making process. Lung cancer remains amongst the deadliest of diseases, and still requires intensive research. In this review, we analyze the merits and drawbacks of the current preclinical models used in lung cancer research, and the position of tumoroids. The introduction of immune cells and healthy regulatory cells in autologous tumoroid models has enabled their application to most recent therapeutic concepts. The possibility of deriving tumoroids from primary tumors within reasonable time has opened a direct approach to patient-specific features, supporting their future role in precision medicine. MDPI 2022-07-12 /pmc/articles/PMC9312903/ /pubmed/35884982 http://dx.doi.org/10.3390/biomedicines10071677 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Lê, Hélène
Seitlinger, Joseph
Lindner, Véronique
Olland, Anne
Falcoz, Pierre-Emmanuel
Benkirane-Jessel, Nadia
Quéméneur, Eric
Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title_full Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title_fullStr Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title_full_unstemmed Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title_short Patient-Derived Lung Tumoroids—An Emerging Technology in Drug Development and Precision Medicine
title_sort patient-derived lung tumoroids—an emerging technology in drug development and precision medicine
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9312903/
https://www.ncbi.nlm.nih.gov/pubmed/35884982
http://dx.doi.org/10.3390/biomedicines10071677
work_keys_str_mv AT lehelene patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT seitlingerjoseph patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT lindnerveronique patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT ollandanne patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT falcozpierreemmanuel patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT benkiranejesselnadia patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine
AT quemeneureric patientderivedlungtumoroidsanemergingtechnologyindrugdevelopmentandprecisionmedicine